Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2022-07-29 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
第四届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 12th meeting of the 4th Supervisory Board of a company. It includes details about the meeting date, attendance, agenda, and voting results. The content focuses on the approval of an employee stock ownership plan unlocking condition and confirms the legality and compliance of the process. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is relatively short (862 characters) and serves as an official meeting resolution announcement rather than a full report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for official announcements that do not fit other specific categories.
2022-07-29 Chinese
葵花药业2021年员工持股计划第一个解锁期业绩考核指标达成情况的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the achievement of performance targets for the first unlocking period of the 2021 employee stock ownership plan of a company. It references legal compliance, approvals by the board and shareholders, and audit reports confirming financial performance. The document is a standalone legal opinion on the employee stock ownership plan's performance criteria achievement, not a full annual report, earnings release, or management discussion. It is not a regulatory announcement or a report publication notice but a detailed legal opinion related to the employee stock ownership plan. This fits best under the category of Regulatory Filings (RNS) as it is a legal opinion document related to compliance and corporate governance matters, not a financial report or announcement of voting results or capital changes.
2022-07-29 Chinese
关于第四届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting agenda item related to the company's 2021 employee stock ownership plan unlocking shares. It references compliance with company law, stock exchange rules, and company articles. The document is short (504 characters) and focuses on governance and board-related matters rather than financial results or detailed reports. It is not a full report but an opinion related to board decisions and governance. Therefore, it fits best under Board/Management Information (MANG).
2022-07-29 Chinese
第四届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 19th meeting of the 4th Board of Directors of a company. It includes details about the meeting date, voting results, and decisions such as approval of an employee stock plan unlocking and investment in a wholly-owned subsidiary. There is no financial data, earnings information, or detailed report content. The document is a formal disclosure of board meeting decisions, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but an official announcement of board decisions.
2022-07-29 Chinese
第四届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 18th meeting of the 4th Board of Directors of the company. It includes details about the meeting date, attendance, agenda items, voting results, and mentions independent directors' opinions. There is no financial data or detailed management discussion, but rather a formal announcement of board decisions, specifically about providing guarantees for a subsidiary's loan. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2022-07-12 Chinese
关于为控股子公司提供担保的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the provision of a guarantee by the parent company to its controlling subsidiary for a loan. It includes details about the guarantee amount, terms, the subsidiary's financial data, board and independent directors' opinions, and cumulative guarantee information. The document is a formal public announcement of a financial guarantee transaction, not a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Capital/Financing Update (CAP) which usually involve fundraising or capital structure changes, nor is it a regulatory certification or voting result. The content aligns best with a Regulatory Filing (RNS) as it is a regulatory announcement about a guarantee provided by the company to a subsidiary, which is a common type of regulatory disclosure in Chinese listed companies.
2022-07-12 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.